RxDoctor Payments Data

Amikjit Reen, MD

Internal Medicine · Ridgecrest, CANPI 1720061112

Payments from drug & device makers

$310in general payments, 2019–2025

Across 17 payments — averaging $18.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$112
  • Supernus Pharmaceuticals, Inc.$71
  • Pfizer$31
  • Biohaven Pharmaceutical Holding Company Ltd.$30
  • Lilly USA, LLC$28
  • Abbott$21
  • plus $18 from 1 others

What the payments were for

  • Food & beverage$310100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$310 in reported general payments places this provider in the 60th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$375,468
Medicare patients
503
Services billed
3,754

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide96$153,227
EliquisApixaban63$74,301
JanuviaSitagliptin Phosphate33$34,084
JardianceEmpagliflozin26$32,097
FarxigaDapagliflozin Propanediol29$31,038
Trelegy ElliptaFluticasone/Umeclidin/Vilanter35$27,273
XareltoRivaroxaban33$21,391
Breo ElliptaFluticasone/Vilanterol22$7,753
Liothyronine Sodium138$6,129
Levothyroxine Sodium390$5,261
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen175$5,078
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen72$4,901
MovantikNaloxegol Oxalate11$4,746
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog13$4,427
Gabapentin87$3,645

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$112$153,22796 claims
PfizerEliquis$31$74,30163 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Ridgecrest

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →